Self-dissolving ureteral stent clears phase II trials

89% of patients satisfied with temporary stent, which is spontaneouslypassed in 8 days

Related Content:

Drug Therapy

Pivotal data for lumasiran in PH1 published in NEJM

Nedosiran explored in primary hyperoxaluria type 3

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria